News Releases
In this section
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 30, 2015
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of 10.0 million shares of its common stock. All of the...
-
Mar 27, 2015
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (NASDAQ:INSM) today announced that on March 26, 2015, it approved non-statutory stock options to purchase 100,000 shares of its common...
-
Mar 23, 201520 Year Industry Veteran Brings Industry, Clinical and Regulatory Experience in Pulmonary and Orphan Diseases
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (NASDAQ:INSM) today announced that Eugene Sullivan, M.D. has joined Insmed as its Chief Medical and Scientific Officer. Dr. Sullivan will...
-
Feb 27, 2015Marketing Authorization Application for ARIKAYCETM Validated by the European Medicines Agency
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq: INSM) today reported financial results for the fourth quarter and year ended December 31, 2014. Highlights of the fourth quarter...
-
Feb 24, 2015
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq: INSM) today announced that Company management will participate at Cowen and Company's 35th Annual Health Care Conference to be...
-
Jan 28, 2015
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the following investor conferences in February: Canaccord...
-
Jan 13, 2015
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (NASDAQ:INSM) today announced that on January 8, 2015, it approved non-statutory stock options to purchase an aggregate of 100,000 shares...
-
Jan 6, 2015
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the 33rd Annual J.P. Morgan Healthcare Conference taking place...
-
Dec 15, 2014
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) today provides a regulatory and clinical update on the Company's development programs. Insmed has submitted its Marketing...
-
Dec 15, 2014Pharmaceutical executive brings 30 years of commercial and operations leadership
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) today announced the appointment of Myrtle Potter to its Board of Directors. Ms. Potter is currently CEO of Myrtle Potter &...
-
Nov 26, 2014
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) today announced that Company management will participate at the following investor conferences in December: Leerink Partners'...
-
Nov 6, 2014Conference Call Begins Today at 8:30 a.m. Eastern Time
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) today reported financial results for the three and nine months ended September 30, 2014. Highlights of the third quarter of...
-
Sep 24, 2014
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM), announces that Company management will participate in the upcoming Leerink Partners' Rare Disease Roundtable taking place...
-
Sep 3, 2014
BRIDGEWATER, NJ -- (Marketwired) -- 09/03/14 -- Insmed Incorporated (NASDAQ: INSM) announces that the Company's novel inhalation technologies for the treatment of orphan pulmonary diseases will be...
-
Aug 18, 2014
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) announced the closing of a $115.1 million underwritten public offering of 10,235,000 shares of common stock, including...
-
Aug 12, 2014
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq: INSM) announced today that it priced an offering of 8.9 million shares of its common stock at a price of $11.25 per share in a...
-
Aug 6, 2014
BRIDGEWATER, N.J. (August 6, 2014) - Insmed Incorporated (Nasdaq: INSM) today reported financial results for the three and six months ended June 30, 2014. Highlights of the second quarter of 2014...
-
Aug 4, 2014Filing Marketing Authorization Application with European Medicines Agency for NTM Lung Disease and CF Indications
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq: INSM) today announced that, following discussions with European regulatory authorities, it intends to file by the end of 2014 a...
-
Jun 20, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 06/20/14 -- Insmed Incorporated (NASDAQ: INSM) today announced that Company management will participate at the JMP Securities Healthcare Conference taking...
-
May 29, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/29/14 -- Insmed Incorporated (NASDAQ: INSM) today announced the appointment of David R. Brennan to its Board of Directors. Mr. Brennanhas more than 37...
-
May 20, 2014Poster Presentation at the American Thoracic Society Annual Meeting 2014
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq:INSM) today announced additional results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for...
-
May 13, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/13/14 -- Insmed Incorporated (NASDAQ: INSM) announces that multiple poster presentations reporting data on ARIKAYCE™, or liposomal amakacin for...
-
May 12, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/12/14 -- Insmed Incorporated (NASDAQ: INSM) announces that Company management will be participating at the Bank of America Merrill Lynch 2014 Health...
-
May 8, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/08/14 -- Insmed Incorporated (NASDAQ: INSM) today reported financial results for the three months ended March 31, 2014. Highlights of the first quarter...
-
Apr 7, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 04/07/14 -- Insmed Incorporated (NASDAQ: INSM) announces that members of the Company's executive management team will be presenting at the 13th Annual...
-
Apr 2, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 04/02/14 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing inhaled anti-infective treatments for patients battling...
-
Mar 26, 2014Conference Call with Insmed Management and Clinical Trial Investigators Will be Held Today at 8:00 a.m. Eastern Time
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq GS:INSM) today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for...
-
Mar 25, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 03/25/14 -- Insmed Incorporated (NASDAQ: INSM) will announce results from its U.S. phase 2 clinical trial of ARIKAYCE™, or liposomal amikacin for...
-
Mar 6, 2014
Mar 06,2014 << Back Insmed Reports 2013 Fourth Quarter and Full Year Financial Results Insmed Reports 2013 Fourth Quarter and Full Year Financial Results MONMOUTH JUNCTION, NJ -- (Marketwired) --...
-
Feb 19, 2014Initial 12-Month Data Demonstrate Long-Term Safety and Durability of Effect
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq GS:INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung...
-
Feb 10, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 02/10/14 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling...
-
Feb 4, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 02/04/14 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling...
-
Feb 4, 2014
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 02/04/14 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling...
-
Nov 5, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 11/05/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling...
-
Nov 1, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 11/01/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling...
-
Oct 23, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 10/23/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...
-
Oct 15, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 10/15/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling...
-
Sep 15, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 09/25/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...
-
Sep 11, 2013
-
Sep 4, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 09/04/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...
-
Aug 7, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 08/07/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...
-
Aug 6, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 08/06/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...
-
Jul 31, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/31/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...
-
Jul 29, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/29/13 -- Insmed Incorporated (NASDAQ: INSM) a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...
-
Jul 22, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/22/13 -- Insmed Incorporated (NASDAQ: INSM) today announced the closing of a $71.8 million underwritten public offering of 6,900,000 shares of common...
-
Jul 17, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/17/13 -- Insmed Incorporated (NASDAQ: INSM) ("Insmed") announced today that it priced an offering of 6.0 million shares of its common stock at a price...
-
Jul 15, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/15/13 -- Insmed Incorporated (NASDAQ: INSM) ("Insmed") announced today that it is offering $60 million of its common stock in a proposed underwritten...
-
Jul 8, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/08/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...
-
Jul 1, 2013ARIKACE Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. FDA for the Treatment of Non-Tuberculous Mycobacteria Lung Infections
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients...
-
Jun 28, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 06/28/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...
-
Jun 28, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 06/28/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...
-
May 14, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/14/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...
-
May 13, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/13/13 -- Insmed Incorporated (NASDAQ: INSM) ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...
-
May 10, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/10/13 -- Insmed Incorporated (NASDAQ: INSM) ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...
-
May 7, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/07/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...
-
May 1, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/01/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...
-
Apr 18, 2013
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 04/18/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...
-
Apr 1, 2013
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 04/01/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...
-
Mar 28, 2013
ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/28/13 -- Insmed Incorporated (NASDAQ: INSM), a...
-
Mar 27, 2013
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/27/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...
-
Mar 18, 2013
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/18/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...
-
Mar 11, 2013
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/11/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...
-
Feb 26, 2013
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 02/26/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...
-
Feb 6, 2013
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 02/06/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...
-
Dec 13, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for patients with high unmet need who are battling...
-
Nov 13, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's CLinical...
-
Nov 12, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Will Lewis, President and Chief...
-
Nov 7, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the appointment of Andrew Drechsler...
-
Nov 7, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported...
-
Oct 24, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, will host a...
-
Sep 28, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced...
-
Aug 30, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that
-
Aug 14, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that
-
Aug 7, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported...
-
Aug 6, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the election of Al Altomari to its...
-
Aug 2, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the U.S. Patent and Trademark...
-
Jul 30, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's Executive Vice...
-
Jul 24, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, will host a conference call on Tuesday, August 7th,...
-
Jul 10, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Renu Gupta, M.D., Executive...
-
Jul 2, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that it has entered into a loan...
-
Jun 27, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal...
-
May 30, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today provided a corporate update, including the Company's current strategic development priorities for ARIKACE® (liposomal...
-
May 23, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize...
-
May 16, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall...
-
May 8, 2012
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2012. Key Recent Highlights: U.S. Food and Drug Administration (FDA)...
-
May 7, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE®...
-
Apr 24, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 8th, 2012, at 8:30 AM ET, to discuss its financial results for the first quarter of...
-
Apr 16, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the initiation of the Company's CLinical Evaluation of ARIKACE phase 3 study (CLEAR-108) of ARIKACE® (liposomal...
-
Mar 13, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011. Key Recent Highlights: Clinical hold...
-
Feb 28, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, March 13th, 2012, at 8:30 AM ET, to discuss its financial results for the fourth quarter...
-
Feb 10, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company is proceeding with a phase 2 clinical trial of ARIKACE® (liposomal amikacin for inhalation) in...
-
Jan 20, 2012
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE®...
-
Nov 14, 2011
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the Lazard Capital...
-
Nov 8, 2011
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011. Key Recent Highlights: FDA...
-
Oct 25, 2011
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, November 8th, 2011, at 8:30 AM ET, to discuss its financial results for the third...
-
Oct 24, 2011
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the...
-
Oct 10, 2011
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the...
-
Sep 26, 2011
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the Sixth Annual...
-
Aug 11, 2011
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the 2011 Wedbush...
-
Aug 8, 2011
Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011. Key Recent Highlights: Announced positive...
Contact Us
